U.S. markets closed
  • S&P 500

    4,280.15
    +72.88 (+1.73%)
     
  • Dow 30

    33,761.05
    +424.38 (+1.27%)
     
  • Nasdaq

    13,047.19
    +267.27 (+2.09%)
     
  • Russell 2000

    2,016.62
    +41.36 (+2.09%)
     
  • Crude Oil

    91.88
    -2.46 (-2.61%)
     
  • Gold

    1,818.90
    +11.70 (+0.65%)
     
  • Silver

    20.83
    +0.49 (+2.39%)
     
  • EUR/USD

    1.0257
    -0.0068 (-0.66%)
     
  • 10-Yr Bond

    2.8490
    -0.0390 (-1.35%)
     
  • GBP/USD

    1.2139
    -0.0064 (-0.52%)
     
  • USD/JPY

    133.4800
    +0.4810 (+0.36%)
     
  • BTC-USD

    24,574.60
    -190.25 (-0.77%)
     
  • CMC Crypto 200

    574.64
    +3.36 (+0.59%)
     
  • FTSE 100

    7,500.89
    +34.98 (+0.47%)
     
  • Nikkei 225

    28,546.98
    +727.65 (+2.62%)
     

Oncocyte Enters $2B Market With Transplant Rejection Monitoring Test

·1 min read
  • Oncocyte Corporation (NASDAQ: OCXcompleted the development and clinical validation of the Laboratory Test for its newly-branded VitaGraft Transplant Monitoring tests for Liver and Kidney, entering a $2 billion US market.

  • The company also opened an Early Adopter Program (EAP), giving access to transplant centers before a potential CMS coverage decision and full commercial launch.

  • VitaGraft has been well-studied across Kidney, Liver, and Heart with over 20 peer-reviewed publications from studies in over 600 patients and over 5,000 samples.

  • It is a simple and non-invasive blood test that has been shown to accurately rule-out rejection or injury following transplant with negative predictive values above 97%, helping avoid around 30% of unnecessary biopsies.

  • Furthermore, the test can assist physicians in optimizing the dosing of immunosuppressive drugs to minimize drug-related side effects and toxicity.

  • Price Action: OCX shares are up 1.20% at $0.87 during the market session on the last check Wednesday.

See more from Benzinga

Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.